You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業-B(01875.HK)公佈年度業績,營收大增239.36%,積極推進產品商業化

格隆匯3月24日丨東曜藥業-B(01875.HK)公佈截至2021年12月31日止年度業績,2021年全年營業收入為人民幣7632.5萬元,同比增長239.36%,主要由於CDMO/CMO業務實現突破性增長,收入人民幣5369萬元。

2021年,研發費用人民幣2.15億元,較2020年的研發費用人民幣2.35億元減少8.72%,主要研發開支來自ADC藥物TAA013的III期臨牀研究,而研發費用的下降因貝伐珠單抗注射液樸欣汀®(TAB008)於年內順利完成III期臨牀研究進入商業化所致。

2021年,東曜藥業順應國際及國內醫藥發展,積極調整戰略規劃,充分發揮競爭優勢,致力於成為國內ADC領域的領導者。公司加大ADC藥物研發及產業佈局,並在創新藥CDMO領域實現了新的突破。伴隨三項產品獲得國家藥品監督管理局("NMPA")上市許可,包括貝伐珠單抗注射液(TAB008;樸欣汀®)、替莫唑胺膠囊(TOZ309;替至安®)及醋酸甲地孕酮口服混懸液(TOM218;美適亞®)的順利上市,與國內知名藥企展開市場推廣的策略合作,同時與科興生物製藥股份有限公司(688136.SH)("科興製藥")就樸欣汀®海外市場商業化許可達成戰略合作,進一步提升了東曜藥業在國內及海外的市場影響力。

依據國家醫藥政策改革及發展趨勢,國家帶量採購和創新藥醫保談判形成常態化,國家醫保目錄不斷擴充,集團協同華潤醫藥商業集團國際貿易有限公司("華潤醫藥商貿")積極推行腫瘤藥物商業運營模式變革,探索腫瘤藥物市場的創新發展,將原有銷售團隊納入合資公司華曜醫藥(蘇州)有限公司("華曜醫藥"),從而合理控制行銷費用,提升公司整體組織效能。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account